First Trust Advisors LP Sells 63,229 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

First Trust Advisors LP lowered its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 58.7% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 44,566 shares of the company's stock after selling 63,229 shares during the quarter. First Trust Advisors LP owned approximately 0.14% of Medpace worth $14,806,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. R Squared Ltd bought a new position in shares of Medpace during the 4th quarter valued at approximately $30,000. SBI Securities Co. Ltd. bought a new position in Medpace during the fourth quarter valued at $31,000. Jones Financial Companies Lllp grew its holdings in Medpace by 2,750.0% during the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock valued at $38,000 after purchasing an additional 110 shares during the period. Lindbrook Capital LLC raised its stake in shares of Medpace by 27.6% in the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after buying an additional 29 shares during the period. Finally, Assetmark Inc. lifted its position in shares of Medpace by 20.1% during the 4th quarter. Assetmark Inc. now owns 173 shares of the company's stock valued at $57,000 after buying an additional 29 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company's stock.

Insiders Place Their Bets

In other Medpace news, Director Fred B. Davenport, Jr. sold 1,712 shares of the stock in a transaction on Thursday, April 24th. The stock was sold at an average price of $301.82, for a total value of $516,715.84. Following the completion of the transaction, the director now owns 2,998 shares in the company, valued at approximately $904,856.36. This represents a 36.35 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 20.30% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Leerink Partnrs raised Medpace to a "hold" rating in a report on Monday, March 24th. Leerink Partners assumed coverage on shares of Medpace in a research report on Monday, March 24th. They issued a "market perform" rating and a $330.00 price target on the stock. TD Cowen cut shares of Medpace from a "buy" rating to a "hold" rating and dropped their price target for the company from $370.00 to $328.00 in a research note on Monday, April 14th. William Blair reiterated a "market perform" rating on shares of Medpace in a research note on Tuesday, April 22nd. Finally, Mizuho dropped their target price on Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 9th. Eleven analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $349.30.

Medpace Stock Up 1.5 %

Shares of MEDP traded up $4.54 during mid-day trading on Friday, hitting $306.79. 92,677 shares of the company's stock traded hands, compared to its average volume of 341,270. The business's 50-day moving average price is $310.62 and its 200-day moving average price is $330.57. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $459.77. The firm has a market capitalization of $8.82 billion, a P/E ratio of 24.29, a PEG ratio of 3.81 and a beta of 1.46.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Monday, April 21st. The company reported $3.67 EPS for the quarter, topping the consensus estimate of $3.06 by $0.61. The business had revenue of $558.57 million during the quarter, compared to analyst estimates of $528.38 million. Medpace had a net margin of 19.17% and a return on equity of 51.48%. During the same period in the prior year, the business earned $3.20 EPS. Sell-side analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.